Abstracts Archive - Page 720 of 2425 - ACR Meeting Abstracts

Abstract Number: 1386 • ACR Convergence 2020
Clinical Correlates and Relevance of the UCLA GIT 2.0 Instrument for Indication for Esophagogastroduodenoscopy and Endoscopic Esophagitis in Real-life Patients with Systemic Sclerosis
Norina Zampatti¹, Alexandru Garaiman¹, Suzana Jordan¹, Britta Maurer², Rucsandra Dobrota¹, Mike Oliver Becker¹, Oliver Distler³ and Carina Mihai¹, ¹Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, Zurich, ²Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, Switzerland, Zurich, ³Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, Switzerland, Zurich, Switzerland
Background/Purpose: Gastrointestinal (GI) tract involvement is the most common of all internal organ involvement in systemic sclerosis (SSc). The University of California at Los Angeles,…
Abstract Number: 1392 • ACR Convergence 2020
Long-Term Tolerability of Aminaphtone in Raynaud’s Phenomenon Secondary to Systemic Sclerosis
Alberto Sulli¹, Sabrina Paolino¹, Giorgia Ferrari¹, Carmen Pizzorni¹, Elvis Hysa¹, Maurizio Cutolo¹ and Emanuele Gotelli¹, ¹Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic, Genoa, Italy
Background/Purpose: Aminaphtone has been used for many years to treat microvascular disorders. In vitro Aminaphtone counteracts vasoconstriction downregulating endothelin-1 production and interferes with adhesion molecules…
Abstract Number: 1391 • ACR Convergence 2020
Associations Between Autoantibodies in Systemic Sclerosis and Cancer in a National Registry
Selma Lazizi¹, Marie Hudson², Murray Baron³, Marvin Fritzler⁴ and Sabrina Hoa⁵, ¹Université de Montréal, Montreal, QC, Canada, ²Division of Rheumatology, Jewish General Hospital, Montréal, QC, Canada, ³Jewish General Hospital, Montreal, QC, Canada, ⁴Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁵Division of Rheumatology, Centre hospitalier de l'Université de Montréal, Montréal, QC, Canada
Background/Purpose: Autoantibodies are useful in systemic sclerosis (SSc) for predicting disease course. Some autoantibodies have been associated with a close temporal relationship with cancer. We…
Abstract Number: 1397 • ACR Convergence 2020
Clinical and Demographic Features of Morphea Patients with Mucocutaneous Involvement: A Cross Sectional Study from the Morphea of Adults and Children Cohort
Smriti Prasad¹, Samantha Black², Shivani Sharma³ and Heidi Jacobe¹, ¹University of Texas Southwestern Medical Center, Dallas, TX, ²The University of Texas Southwestern Medical Center, Dallas, TX, ³University of Texas Southwestern, Dallas, TX
Background/Purpose: Morphea is an autoimmune skin condition that produces skin and soft tissue sclerosis. While clinical manifestations of morphea have been well-described, mucocutaneous findings such…
Abstract Number: 1399 • ACR Convergence 2020
Differential Impacts of TNFa Inhibitors on the Expression of Th Cytokines
Ching-Huang Ho¹, Andrea Silva¹ and I-Cheng Ho², ¹Brigham and Women's Hospital, Boston, MA, ²Birgham and Women's Hospital, Boston, MA
Background/Purpose: Inhibition of TNFα has emerged as an effective therapeutic approach for many autoimmune/inflammatory diseases.While the efficacy and safety profile of the five FDA-approved TNFis…
Abstract Number: 1394 • ACR Convergence 2020
Pathway to Systemic Sclerosis: Concerning Patients’ Experiences During the Diagnostic Process
Fennell Patricia¹, Lee Shapiro², Nancy Dorr³, Roberta Lukasiewicz⁴, Frank Houser⁵ and Madison Taylor⁶, ¹Albany Health Management Associates, Steffens Scleroderma Foundation, Albany, NY, ²Albany Medical College, Stillwater, NY, ³The College of Saint Rose, Albany, NY, ⁴Steffens Scleroderma Foundation, Albany, NY, ⁵The College of Saint Rose, Nassau, NY, ⁶The College of Saint Rose, Mississauga, ON, Canada
Background/Purpose: Receiving a diagnosis of systemic sclerosis (SSc) can be straightforward process for some, whereas others have a circuitous route. Given that complications can often…
Abstract Number: 1389 • ACR Convergence 2020
Clinical Characteristics and Treatment Outcome of a Cohort of Patients with Joint and Fascial Involvement in the Context of Chronic Graft versus Host Disease
Cristina Hidalgo Calleja¹, Concepción Román Curto², Luis Gómez-Lechón³, Maria Elisa Acosta², Olga Compán⁴, Sonia Pastor², Carlos Montilla Morales², Lucía Pantoja Zarza⁵, María Dolores Sánchez González⁶ and Lucía López Corral², ¹Hospital Universitario Salamanca, Salamanca, Spain, ²Hospital Universitario de Salamanca, Salamanca, Spain, ³Hospital Francesc de Borga de Gandía, Valencia, Spain, ⁴Hospital Universitario de Salamanca, ´Salamanca, Spain, ⁵Complejo Asistencial Hospital General de Segovia, Segovia, Spain, ⁶Hospital Clínico Universitario de Valladolid, Valladolid, Spain
Background/Purpose: Chronic graft-vs-host disease (cGVHD) is a major late complication of allogeneic hematopoietic stem cell transplantation (alloHSCT), typically occurring within three years post-transplant and affecting…
Abstract Number: 1402 • ACR Convergence 2020
Galectin-3 Decreases the Activity of 4-1BB by Facilitating Its Decoy Surface Binding in Rheumatoid Arthritis
Morten Aagaard Nielsen¹, Kristian Juul-Madsen², John Stegmayr³, Chao Gao⁴, Tue Wenzel Kragstrup¹, Malene Hvid¹, Thomas Vorup-Jensen¹, Richard Cummings⁵, Hakon Leffler³ and Bent Deleuran¹, ¹Aarhus University, Aarhus, Denmark, ²Aarhus University, Aarhus, Midtjylland, Denmark, ³Lund University, Lund, Sweden, ⁴Beth Israel Deaconess Medical Center Harvard Medical School, Boston, MA, ⁵Beth Israel Deaconess Medical Center Harvard Medical School, Boston
Background/Purpose: Orchestration of immune checkpoints is central for the outcome of immune activation, especially in patients with rheumatoid arthritis (RA). We have previously shown that…
Abstract Number: 1405 • ACR Convergence 2020
Evaluating the Cellular Composition of Anti-synthetase Syndrome and Dermatomyositis Skin Lesions Using Image Mass Cytometry
Jay Patel¹, Adarsh Ravishankar¹, Spandana Maddukuri², Christina Bax³ and Victoria Werth⁴, ¹University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, ²University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Montville, NJ, ³University of Pennsylvania, Department of Dermatology, Philadelphia, ⁴University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, PA
Background/Purpose: Antisynthetase syndrome (AS) is a systemic autoimmune disorder characterized by the presence of anti-aminoacyl-tRNA synthetase antibodies, myositis, interstitial lung disease (ILD), mechanics hands, and…
Abstract Number: 1406 • ACR Convergence 2020
LAG-3+ T Cells Are Diminished in Active Psoriatic Arthritis Patients and Their Restoration in Vitro Is Mediated by TNF Inhibitors
Smadar Gertel¹, Ari Polachek², Victoria Furer³, David Levartovsky³ and Ori Elkayam⁴, ¹Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel, ²Tel Aviv Sourasky Medical Center, Petah-Tikva, Israel, ³Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ⁴Tel Aviv Sourasky Medical Center, Tel-Aviv, Israel
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory arthritis associated with psoriasis. Aberrant T cell regulation has been implicated in the process of inflammation in…
Abstract Number: 1401 • ACR Convergence 2020
Disease Mutation That Weakens ZAP70 Autoinhibition Enhances Responses to Weak and Self Ligands
Lin Shen¹, Mehrdad Matloubian¹, Theresa Kadlecek² and Arthur Weiss¹, ¹University of California, San Francisco, San Francisco, CA, ²University of California, San Francisco, San Francisco
Background/Purpose: ZAP70, a cytoplasmic protein tyrosine kinase, is critical for TCR signaling and T cell development. Complete loss of function of ZAP70 in humans causes…
Abstract Number: 1412 • ACR Convergence 2020
A T Cell Intrinsic Role for Nod2 in Suppression of Th17-Mediated Experimental Arthritis and Uveitis: Implications for Blau Syndrome
Ruth Napier¹, Ellen Lee¹, Emily Vance¹, Sydney Lashley², Luke Uebelhoer³, Christina Lancioni³, Richard Vehe⁴, Bryce Binstadt⁴, Rachel Caspi⁵ and Holly Rosenzweig¹, ¹Oregon Health & Science University and VA Portland Health Care System, Portland, OR, ²VA Portland Health Care System, Portland, OR, ³Oregon Health & Science University, Portland, ⁴University of Minnesota, Minneapolis, MN, ⁵NIH, Bethesda, MD
Background/Purpose: Mutations in nucleotide-binding oligomerization domain-containing protein 2 (NOD2) cause Blau syndrome, an inflammatory disorder characterized by uveitis, dermatitis, and polyarthritis. The antimicrobial functions of NOD2 are…
Abstract Number: 1409 • ACR Convergence 2020
Lack of Conventional Acinar Cells in the Salivary Gland Following Anti PD-L1 and anti-PD-1 Immune Checkpoint Inhibitor Therapy
Sarah Pringle¹, Bert van der Vegt¹, Xiaoyan Wang¹, Nico van Bakelen¹, Arjan Vissink¹, Frans Kroese² and Hendrika Bootsma², ¹UMCG, Groningen, ²University Medical Centre Groningen, Groningen, Netherlands
Background/Purpose: Salivary glands (SGs) can be damaged by immune checkpoint inhibitor (ICI) therapy. In patients with ICI-induced SG dysfunction, 60% progress to fulfill the ACR-EULAR…
Abstract Number: 1404 • ACR Convergence 2020
Investigating the Dermatomyositis Skin Inflammatory Infiltrate Using Image Mass Cytometry
Jay Patel¹, Spandana Maddukuri², Yubin Li³, Christina Bax⁴ and Victoria Werth³, ¹University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, ²University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Montville, NJ, ³University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, PA, ⁴University of Pennsylvania, Department of Dermatology, Philadelphia
Background/Purpose: Dermatomyositis (DM) is a systemic autoimmune disease affecting the skin and muscles, among other organs. The inflammatory infiltrate in skin has not been fully…
Abstract Number: 1296 • ACR Convergence 2020
Associations of Metabolic Syndrome and Adipokines in SLE
Diane Apostolopoulos¹, Fabien Vincent², Rachel Koelmeyer², Alberta Hoi¹ and Eric Morand³, ¹Monash University, Melbourne, Victoria, Australia, ²Monash University, Clayton, Victoria, Australia, ³Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia
Background/Purpose: Metabolic syndrome (MetS) is a chronic pro-inflammatory and pro-thrombotic state associated with increased atherosclerosis, cardiovascular events and type 2 diabetes. It is diagnosed in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].